![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri
The oligopeptide transporter may be exploited to enhance the absorption of drugs by synthesizing their dipeptide ester prodrugs, which may be recognized as its substrates. Various dipeptide esters of acyclovir (ACV), an antiviral nucleoside analog, were synthesized. Enzymatic hydrolysis and affinity of the prodrugs toward the human intestinal peptide transporter hPEPT1 were studied using the human intestinal Caco-2 cell line. Affinity studies were performed by inhibiting the uptake of [3H]glycylsarcosine by the prodrugs. The uptake of glycylsarcosine was found to be saturable at higher concentrations and was competitively inhibited by the prodrugs of ACV. All prodrugs except Tyr-Gly-ACV demonstrated a higher affinity (1.41–4.96 mM) toward hPEPT1 than cephalexin (8.19 ± 2.12 mM), which was used as a positive control. Two prodrugs, Gly-Val-ACV and Val-Val-ACV, showed comparable affinity to Val-ACV, an amino acid prodrug of ACV recognized by PEPT1/PEPT2. The permeability of Gly-Val-ACV (2.99 ± 0.59 x 10-6 cm/s) across Caco-2 was comparable with that of Val-ACV (3.01 ± 0.21 x 10-6 cm/s) and was significantly inhibited (63%) in presence of glycylsarcosine. The transport of GVACV across Caco-2 was saturable at higher concentrations, and the parameters were calculated as Km 3.16 ± 0.31 mM and Vmax 0.014 ± 0.00058 nmol cm-2 min-1. Overall, the results suggest that the dipeptide prodrugs of ACV have a high affinity toward the intestinal oligopeptide transporter hPEPT1 and therefore seem to be promising candidates in the treatment of ocular and oral herpesvirus infections, because cornea and intestinal epithelia seem to express the oligopeptide transporters.
Address correspondence to: Dr. Ashim K. Mitra, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Rd., Kansas City, MO 64110-2499. E-mail: mitraa{at}umkc.edu
This article has been cited by other articles:
|
|
 |
|
  B. S. Anand, S. Katragadda, and A. K. Mitra Pharmacokinetics of Novel Dipeptide Ester Prodrugs of Acyclovir after Oral Administration: Intestinal Absorption and Liver Metabolism J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 659 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hatanaka, M. Haramura, Y.-J. Fei, S. Miyauchi, C. C. Bridges, P. S. Ganapathy, S. B. Smith, V. Ganapathy, and M. E. Ganapathy Transport of Amino Acid-Based Prodrugs by the Na+- and Cl--Coupled Amino Acid Transporter ATB0,+ and Expression of the Transporter in Tissues Amenable for Drug Delivery J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1138 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Kulkarni, I. S. Haworth, T. Uchiyama, and V. H. L. Lee Analysis of Transmembrane Segment 7 of the Dipeptide Transporter hPepT1 by Cysteine-scanning Mutagenesis J. Biol. Chem., December 19, 2003; 278(51): 51833 - 51840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Anand, J. M. Hill, S. Dey, K. Maruyama, P. S. Bhattacharjee, M. E. Myles, Y. E. Nashed, and A. K. Mitra In Vivo Antiviral Efficacy of a Dipeptide Acyclovir Prodrug, Val-Val-Acyclovir, against HSV-1 Epithelial and Stromal Keratitis in the Rabbit Eye Model Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2529 - 2534. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
